ArticleAmerican journal of translational research2026
Predictive value of quantitative CT-derived emphysema heterogeneity for outcomes following bronchoscopic lung volume reduction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the predictive value of quantitative CT-derived emphysema heterogeneity for clinical response to bronchoscopic lung volume reduction (BLVR).
methodsThis retrospective study included 150 patients who underwent bronchoscopic lung volume reduction (BLVR) between January 2023 and November 2025, of whom 82 were responders and 68 were non-responders. The primary endpoint was the BLVR outcome at 6 months post-procedure, defined as a 15% improvement in forced expiratory volume in one second (FEV1) or a 450 mL improvement in target lobe volume. Secondary endpoints included changes in Chronic Obstructive Lung Disease Assessment Test score, modified Medical Research Council dyspnea score, carbon monoxide diffusion capacity (DLCO), and 6-minute walk test (6MWT). Quantitative CT measurements such as emphysema heterogeneity index (EHI), low attenuation area percentage (LAA%), lung fissure integrity, and air trapping heterogeneity were used as baseline lung structural pmeasures. Multivariate logistic regression analysis was used to identify independent predictors of treatment response.
resultsResponders exhibited significantly greater heterogeneity in emphysema: higher EHI, more significant differences in lobar destruction, and a higher proportion of heterogeneous voxels (all P<0.001). Structural parameters also differentiated responders, with responders showing more pronounced lobar volume asymmetry, higher target lobe destruction rate, and decreased vascular density (all P<0.001). Functional quantitative CT revealed markedly higher heterogeneity in air retention (P<0.001), more pronounced ventilation asymmetry (P<0.001), and larger gas retention clusters (all P<0.001) in responders. Responders also had more intact lung fissures and a lower probability of collateral ventilation (both P<0.001). Better preservation of airway morphology was observed, characterized by thinner airway walls (P<0.01), larger lumens (P<0.001), and a greater number of airways (P<0.001). Multivariate analysis showed that the EHI (OR 0.114, P<0.001), ≥90% integrity of the lung fissure (OR 0.888, P<0.001), and immediate target lobe volume reduction ≥700 mL (OR 0.106, P<0.001) were independent predictors of BLVR response.
conclusionQuantitative CT-derived assessment of emphysema heterogeneity provides a strong and clinically significant predictor of treatment response to bronchoscopic lung volume reduction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.